Wellington Management Group LLP Buys 22,137 Shares of Maze Therapeutics, Inc. $MAZE

Posted by Brenda Bartman on Sep 11th, 2026

Wellington Management Group LLP boosted its stake in Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) by 36.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,724 shares of the company’s stock after purchasing an additional 22,137 shares during the quarter. Wellington Management Group LLP owned about 0.15% of Maze Therapeutics worth $2,468,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MAZE. ARCH Venture Management LLC bought a new position in Maze Therapeutics during the second quarter valued at $122,983,582. Alphabet Inc. bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth about $41,435,000. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $133,502,907. Spruce Street Capital LP purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $5,970,000. Finally, Bank of America Corp DE lifted its holdings in shares of Maze Therapeutics by 961.3% in the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock valued at $5,823,000 after acquiring an additional 176,703 shares during the last quarter.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $24.82 on Friday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.38 billion, a PE ratio of -9.85 and a beta of 2.17. Maze Therapeutics, Inc. has a 12-month low of $20.00 and a 12-month high of $53.65. The business’s fifty day simple moving average is $28.33 and its 200-day simple moving average is $30.50.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). Analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Check Out Our Latest Analysis on MAZE

Insider Buying and Selling

In related news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the sale, the insider owned 7,007 shares in the company, valued at approximately $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $84,350.43. Following the sale, the insider owned 32,316 shares in the company, valued at $840,539.16. This trade represents a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 219,317 shares of company stock valued at $5,989,040 over the last quarter. 5.30% of the stock is currently owned by company insiders.

Maze Therapeutics Profile

(Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.